in stock
Larotrectinib (LOXO-101) is an ATP-competitive oral, selective inhibitor of the tropomyosin-related kinase (TRK) family receptors, with low nanomolar 50% inhibitory concentrations against all three isoforms (TRKA, B, and C).
上海厚博生物科技有限公司
联系商家时请提及chemicalbook,有助于交易顺利完成!